Aimaz Afrough, MD
Hematology · Dallas, TXNPI 1477964518
Payments from drug & device makers
Across 222 payments — averaging $6065.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1M
- AbbVie$172K
- Regeneron$148K
- Johnson & Johnson$4K
- Sanofi$4K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $6K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 44 | $1,010,021 |
| AbbVie | 19 | $171,528 |
| Regeneron | 47 | $148,268 |
| Johnson & Johnson | 12 | $4,401 |
| Sanofi | 5 | $3,760 |
| E.r. Squibb & Sons, L.L.C. | 8 | $2,658 |
| Pfizer | 17 | $2,405 |
| Janssen Scientific Affairs, LLC | 9 | $1,802 |
| Bristol Myers Squibb | 18 | $332 |
| Karyopharm Therapeutics Inc. | 3 | $221 |
| Sanofi-aventis U.S. LLC | 1 | $174 |
| AstraZeneca | 7 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $133 |
| Beigene USA, Inc. | 1 | $125 |
| Lilly USA, LLC | 8 | $115 |
| Legend Biotech USA Inc. | 1 | $104 |
| Astrazeneca UK Limited | 1 | $96 |
| Incyte Corporation | 4 | $66 |
| Adaptive Biotechnologies Corporation | 1 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Agios Pharmaceuticals, Inc. | 3 | $45 |
| Daiichi Sankyo Inc. | 1 | $31 |
| Tempus AI, Inc | 2 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Eurofins Viracor, LLC | 1 | $8 |
How this compares
$1,346,631 in reported general payments places this provider in the 85th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Dallas
- Arthur FrankelDallas$3.5M
- Ankit KansagraDallas$2.7M
- Jean Antoine RibeilDallas$205K
- Taha BatDallas$81K
- Ameen SalahudeenDallas$72K
- Alecia NeroDallas$48K
- Mingyi ChenDallas$37K
- Navid SadeghiDallas$20K
- Kirthi KumarDallas$19K
- Natalie BavliDallas$822
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.